32,768 Shares in Zimmer Biomet Holdings, Inc. $ZBH Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 32,768 shares of the medical equipment provider’s stock, valued at approximately $2,821,000.

Several other large investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. raised its stake in shares of Zimmer Biomet by 9.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after acquiring an additional 13,883 shares during the last quarter. Morningstar Investment Management LLC grew its position in Zimmer Biomet by 235.4% during the 4th quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock worth $5,204,000 after acquiring an additional 40,610 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in Zimmer Biomet by 257.2% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock valued at $3,091,000 after purchasing an additional 24,748 shares in the last quarter. Robertson Stephens Wealth Management LLC bought a new position in Zimmer Biomet in the 4th quarter valued at $1,131,000. Finally, CIBC Asset Management Inc boosted its stake in Zimmer Biomet by 67.6% in the fourth quarter. CIBC Asset Management Inc now owns 46,516 shares of the medical equipment provider’s stock worth $4,183,000 after purchasing an additional 18,769 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 1.6%

Shares of NYSE ZBH opened at $101.10 on Friday. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $19.28 billion, a PE ratio of 24.60, a price-to-earnings-growth ratio of 2.70 and a beta of 0.45. The firm’s 50-day moving average is $93.88 and its 200-day moving average is $91.45. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $106.88.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same period in the previous year, the firm earned $2.07 earnings per share. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ZBH. Weiss Ratings upgraded Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, August 4th. Citigroup decreased their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Stifel Nicolaus raised their price objective on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. BMO Capital Markets reiterated a “market perform” rating and set a $96.00 target price on shares of Zimmer Biomet in a research report on Thursday, August 6th. Finally, Royal Bank Of Canada raised their price target on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.